Skip to main content

Advertisement

SpringerLink
Log in

Management of primary intraocular lymphoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid cells invade the retina, vitreous body, or optic nerve head. It is usually a large B-cell non-Hodgkin’s lymphoma. PIOL typically presents as a vitritis that is unresponsive to corticosteroid therapy. Diagnosis of PIOL requires pathologic confirmation of malignant cells in specimens of the cerebrospinal fluid, vitreous, or chorioretinal biopsies. The optimal therapy for PIOL has yet to be determined. It is generally believed that PIOL should be treated with a combination of systemic chemotherapy, including high-dose methotrexate and radiotherapy. However, several new developments for PIOL with central nervous system involvement have been reported, including intrathecal therapy and autologous stem-cell transplantation. In addition, intravitreal methotrexate has been successful in the treatment of isolated recurrent ocular disease. This article provides an overview of treatment modalities for initial, recurrent, and relapsed PIOL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Freeman LN, Schachat AP, Knox DL, et al.: Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology 1987, 94:1631–1639.

    PubMed  CAS  Google Scholar 

  2. Hoffman PM, McKelvie P, Hall, AJ, et al.: Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye 2003, 17:513–521.

    Article  PubMed  CAS  Google Scholar 

  3. Whitcup SM, de Smet MD, Rubin BI, et al.: Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology 1993, 100:1399–406.

    PubMed  CAS  Google Scholar 

  4. DeAngelis LM: Brain tumors. N Engl J Med 2001, 344:114–123.

    Article  PubMed  CAS  Google Scholar 

  5. Schabet M: Epidemiology of primary CNS lymphoma. J Neurooncol 1999, 43:199–201.

    Article  PubMed  CAS  Google Scholar 

  6. Velez G, Chan CC, Csaky KG: Fluorescein angiographic findings in primary intraocular lymphoma. Retina 2002, 22:37–43. Details most common findings on fluorescein angiography in 17 patients with PIOL.

    Article  PubMed  Google Scholar 

  7. Cassoux N, Merle-Beral H, Leblond V, et al.: Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 2000, 8:243–250.

    Article  PubMed  CAS  Google Scholar 

  8. Chan CC, Wallace DJ: Intraocular lymphoma: update on diagnosis and management. Cancer Control 2004, 11:1–11.

    Google Scholar 

  9. Hormigo A, DeAngelis LM: Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma 2003, 4:22–29.

    PubMed  Google Scholar 

  10. Chan CC: Molecular pathology of primary intraocular lymphomas. Trans Am Ophthalmol Soc 2003, 101:43–60. Presents the results of cytologic, cytokine, and molecular analyses of the PIOL patients seen at the National Eye Institute.

    Google Scholar 

  11. Gorochov G, Parizot C, Bodaghi B: Characterization of vitreous B-cell infiltrates in patients with primary ocular lymphoma, using CDR3 size polymorphism analysis of antibody transcripts. Invest Ophthalmol Vis Sci 2003, 44:5235–5241.

    Article  PubMed  Google Scholar 

  12. Wolf LA, Reed GF, Buggage RR, et al.: Vitreous cytokine levels. Ophthalmology 2003, 110:1671–1672. IL-10:IL-6 ratio greater than 1 in vitreous specimens is suggestive of PIOL.

    Article  PubMed  Google Scholar 

  13. Chan CC, Whitcup SM, Solomon D, et al.: Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. Am J Ophthalmol 1995, 120:671–673.

    PubMed  CAS  Google Scholar 

  14. Whitcup SM, Stark-Vancs V, Wittes RE, et al.: Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 1997, 115:1157–1160.

    PubMed  CAS  Google Scholar 

  15. Cassoux N, Merle-Beral H, LeHoang P, et al.: Interleukin-10 and intraocular-central nervous system lymphoma. Ophthalmology 2001, 108:426–427.

    Article  PubMed  CAS  Google Scholar 

  16. Chan CC, Buggage RR, Nussenblatt RB: Intraocular lymphoma. Curr Opin Ophthalmol 2002,13:411–418.

    Article  PubMed  Google Scholar 

  17. O’Neill BP, O’Fallon JR, Earle JD, et al.: Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Physics 1995, 33:663–673.

    Article  CAS  Google Scholar 

  18. Nelson DF, Martz KL, Bonner H, et al.: Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Physics 1992, 23:9–17.

    CAS  Google Scholar 

  19. DeAngelis LM: Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol 1999, 43:249–57. Comparison of combined chemotherapy and radiation for the treatment of PCNSL with radiotherapy alone.

    Article  PubMed  CAS  Google Scholar 

  20. DeAngelis LM, Yahalom J, Thaler HT, et al.: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992, 10:635–643.

    PubMed  CAS  Google Scholar 

  21. DeAngelis LM, Seiferheld W, Schold SC, et al.: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10. J Clin Oncol 2002, 20:4643–4648.

    Article  PubMed  Google Scholar 

  22. Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 1998, 16:859–863.

    PubMed  CAS  Google Scholar 

  23. Gill MK, Jampol LM: Variations in the presentation of primary intraocular lymphoma: case reports and a review. Surv Ophthalmol 2001, 45:463–471.

    Article  PubMed  CAS  Google Scholar 

  24. Char DH, Ljung BM, Miller T, Phillips T: Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 1988, 95:625–630.

    PubMed  CAS  Google Scholar 

  25. Margolis L, Fraser R, Lichter A, et al.: The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 1980, 45:688–692.

    Article  PubMed  CAS  Google Scholar 

  26. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM: The clinical spectrum of ocular lymphoma. Cancer 1993, 72:843–849.

    Article  PubMed  CAS  Google Scholar 

  27. Buggage RR, Chan CC, Nussenblatt RB: Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 2001, 13:137–142.

    Article  PubMed  CAS  Google Scholar 

  28. Cunha-Vaz J: The blood-ocular barriers. Surv Ophthalmol 1979, 23:279–296.

    Article  PubMed  CAS  Google Scholar 

  29. Baumann MA, Ritch PS, Hande KR, et al.: Treatment of intraocular lymphoma with high-dose Ara-C. Cancer 1986, 57:1273–1275.

    Article  PubMed  CAS  Google Scholar 

  30. de Smet MD, Stark-Vancs V, Kohler D, et al.: Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 1996, 121:442–444.

    PubMed  Google Scholar 

  31. Henson JW, Yang J, Batchelor T: Intraocular methotrexate level after high-dose intravenous infusion. J Clin Oncol 1999, 17:1329.

    PubMed  CAS  Google Scholar 

  32. Batchelor TT, Kolak G, Ciordia R, et al.: High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 2003, 9:711–715.

    PubMed  CAS  Google Scholar 

  33. Batchelor T, Carson K, O’Neill A, et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003, 21:1044–1049.

    Article  PubMed  CAS  Google Scholar 

  34. Valluri S, Moorthy RS, Khan A, Rao NA: Combination treatment of intraocular lymphoma. Retina 1995, 15:125–129.

    Article  PubMed  CAS  Google Scholar 

  35. Strauchen JA, Dalton J, Friedman AH: Chemotherapy in the management of intraocular lymphoma. Cancer 1989, 63:1918–1921.

    Article  PubMed  CAS  Google Scholar 

  36. Ferreri AJ, Blay JY, Reni M, et al.: Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 2002, 13:531–538.

    Article  PubMed  CAS  Google Scholar 

  37. de Smet MD, Vancs VS, Kohler D, et al.: Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 1999, 83:448–451.

    Article  PubMed  Google Scholar 

  38. Fishburne BC, Wilson DJ, Rosenbaum JT, et al.: Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997, 15:1152–1156.

    Google Scholar 

  39. Smith JR, Rosenbaum JT, Wilson DJ, et al.: Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002, 109:1709–1716. Largest study of intravitreal methotrexate for ocular disease; included 16 patients.

    Article  PubMed  Google Scholar 

  40. Velez G, Yuan P, Sung C, et al.: Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 2001, 119:1518–1524.

    PubMed  CAS  Google Scholar 

  41. Mason JO, Fischer DH: Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma. Ophthalmology 2003, 110:1241–1244.

    Article  PubMed  Google Scholar 

  42. Soussain C, Suzan F, Hoang-Xuan K, et al.: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001, 19:742–749. Intensive chemotherapy and stem cell rescue can be an effective combination treatment for patients with recurrent PCNSL and PIOL.

    PubMed  CAS  Google Scholar 

  43. Abrey LE, Moskowitz CH, Mason WP, et al.: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003, 21:4151–4156.

    Article  PubMed  CAS  Google Scholar 

  44. Schulz H, Pels H, Schmidt-Wolf I, et al.: Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004, 89:753–754.

    PubMed  CAS  Google Scholar 

  45. Pels H, Schulz H, Schlegel U, Engert A: Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003, 26:351–354.

    Article  PubMed  CAS  Google Scholar 

  46. Feugier P, Virion JM, Tilly H, et al.: Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004, 15:129–133.

    Article  PubMed  CAS  Google Scholar 

  47. Rubenstein JL, Combs D, Rosenberg J, et al.: Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003, 101:466–468.

    Article  PubMed  CAS  Google Scholar 

  48. Nasir S, DeAngelis LM: Update on the management of primary CNS lymphoma. Oncology 2000, 14:228–234.

    PubMed  CAS  Google Scholar 

  49. Blay JY, Conroy T, Chevreau C, et al.: High-dose methotrexate for treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998, 16:864–870.

    PubMed  CAS  Google Scholar 

  50. Corry J, Smith JG, Wirth A, et al.: Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Physics 1998, 4:615–620.

    Article  Google Scholar 

  51. Hormigo A, Abrey LE, Heinemann MH, DeAngelis LM: Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 2004, 126:202–208. Study of 31 patients revealed the importance of early treatment of PIOL before CNS progression.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, #443, 77030, Houston, TX, USA

    Stella K. Kim MD

Authors
  1. Stella K. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chi-Chao Chan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dana J. Wallace BS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, S.K., Chan, CC. & Wallace, D.J. Management of primary intraocular lymphoma. Curr Oncol Rep 7, 74–79 (2005). https://doi.org/10.1007/s11912-005-0029-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0029-6

Keywords

Search

Navigation